Peanut Allergy Clinical Trials Assessment 2025: Competitive Landscape, FDA Approvals, Therapies, Emerging Drugs, Mechanism of Action, Route of Administration by DelveInsight

As per DelveInsight's assessment, globally, Peanut Allergy pipeline constitutes 12+ key companies continuously working towards developing 15+ Peanut Allergy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments.
DelveInsight's ' Peanut Allergy Competitive Landscape 2025' report provides comprehensive global coverage of pipeline multiple sclerosis medication in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the multiple sclerosis pipeline domain.
The analysis delivers granular coverage of drug profiles, mechanisms of action, routes of administration, molecular types, and therapeutic assessments while also mapping active, inactive, and discontinued programs. The report positions stakeholders to make informed decisions by identifying clinical advances, R&D collaborations, regulatory progress, and unmet needs within the peanut allergy treatment domain.

Get a Detailed Overview of the Peanut Allergy Clinical Trial Activities and Regulatory Developments in the domain @ https://www.delveinsight.com/report-store/peanut-allergy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Highlights from the Peanut Allergy Pipeline Report
• More than 10 companies are actively engaged in developing innovative peanut allergy therapies, representing 12+ drug candidates spanning early discovery through late-stage clinical trials.
• In August 2025, DBV Technologies initiated a Phase III randomized, double-blind, placebo-controlled study evaluating DBV712 (250 mcg) in children aged 1-3 years with peanut allergy. Subjects completing the six-month study period will transition to an 18-month open-label extension (OLE).
• In February 2025, Stallergenes Greer, a global leader in allergy therapeutics, today announced the launch of Palforzia® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] in the U.S to treat toddler patients, ages 1 through 3 years, with a confirmed diagnosis of peanut allergy.
• In November 2024:- IgGenix Australia Pty Ltd- A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study with Single Blind Sentinel Period to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IGNX001 in Peanut-Allergic Participants. The goal of this randomized, double-blind, placebo-controlled, single ascending dose clinical trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of IGNX001 in peanut-allergic adults and older Adolescents.
• Diverse industry participation: Leading Peanut Allergy companies include DBV Technologies, Regeneron Pharmaceuticals, Cour Pharmaceutical, HAL Allergy, InnoUp Farma S.L., Vedanta Biosciences, Astellas Pharma, Intrommune Therapeutics, Genentech, ASIT biotech, BlueWillow Biologics, Allergy Therapeutics, Alladapt Immunotherapeutics, Desentum, Camallergy, Prota Therapeutics, IgGenix, among others.
• Promising Peanut Allergy therapeutic candidates: Emerging assets such as Dupilumab, AR101, CNP-201, Etokimab, HAL-MPE1, ASP0892, INT301, and others showcase novel approaches to disease management.

Learn More about the Clinical and Commercial Development Activities in the Peanut Allergy Therapeutics Domain @ https://www.delveinsight.com/report-store/peanut-allergy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Peanut Allergy Drug Profiles
DBV712 - DBV Technologies
DBV712 is an investigational epicutaneous immunotherapy (EPIT) designed for the treatment of peanut allergy. Delivered through a skin patch, the therapy administers microgram quantities of peanut protein to gradually desensitize the immune system and mitigate allergic reactions from accidental exposures. Its non-invasive mechanism provides a favorable safety profile and offers a more convenient alternative to oral immunotherapy, particularly suited for pediatric patients. The program is currently under Phase III clinical evaluation.
PVX-108 - Aravax Pty Ltd
PVX-108 represents a peptide-based immunotherapy tailored to restore immune tolerance without the risks associated with whole peanut protein exposure. Unlike conventional immunotherapies, PVX-108 excludes allergenic proteins, thereby eliminating the risk of mast cell and basophil activation. Its design supports needle-free intradermal administration with a monthly dosing regimen and no requirement for dose escalation. Currently in Phase II trials, PVX-108 offers a differentiated risk-benefit profile.
INP20 - InnoUp Farma S.L.
INP20 leverages nanoparticle-based oral vaccine technology encapsulating whole peanut extract for targeted gastrointestinal delivery. This controlled-release platform reduces systemic allergen exposure, minimizes severe allergic reactions, and promotes immunomodulation through antigen-presenting cells. Positioned in Phase I/II development, INP20 demonstrates potential for long-term immune tolerance induction while maintaining a simplified dosing protocol and favorable safety outlook.

Get an in-depth Assessment of the Emerging Therapies and Peanut Allergy Companies Actively Working in the Market @ https://www.delveinsight.com/sample-request/peanut-allergy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Therapeutic Landscape Assessment
The DelveInsight pipeline report offers a detailed therapeutic assessment segmented across multiple parameters:
By Route of Administration (ROA):
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

By Molecule Type:
• Recombinant fusion proteins
• Small molecules
• Monoclonal antibodies
• Peptides
• Polymers
• Gene therapies

By Developmental Stage:
• Discovery
• Pre-clinical
• Phase I
• Phase II
• Phase III

By Product Type:
• Monotherapy
• Combination therapy
• Hybrid (Mono/Combination)
This stratification provides stakeholders with actionable insights into the current state of innovation, clinical feasibility, and future positioning of investigational products.

Strategic Collaborations and Market Dynamics
The report further highlights critical collaborations, licensing agreements, and financing activities shaping the competitive landscape. These partnerships between biopharmaceutical companies, academic institutions, and research consortia are accelerating innovation in immunotherapy approaches for peanut allergy.
The global peanut allergy therapeutics market remains underserved, with significant unmet needs around safety, tolerability, and long-term efficacy. Current innovations emphasize:
• Improved safety mechanisms to reduce the risk of anaphylaxis.
• Patient-friendly administration routes to enhance compliance.
• Long-lasting immune tolerance induction beyond symptomatic control.

Request for Sample PDF to Understand More About the Peanut Allergy Treatment Outlook and Future Perspectives @ https://www.delveinsight.com/sample-request/peanut-allergy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Analytical Perspective
According to DelveInsight analysts, the peanut allergy therapeutic landscape is undergoing a paradigm shift from traditional allergen avoidance and emergency epinephrine use toward preventive and disease-modifying therapies. Late-stage candidates such as DBV712 are poised to potentially redefine the standard of care, while mid- and early-stage products like PVX-108 and INP20 exemplify next-generation immunotherapy innovation.

Scope of the Report
• Geographical Coverage: Global
• Key Companies Profiled: DBV Technologies, Regeneron Pharmaceuticals, Cour Pharmaceutical, HAL Allergy, InnoUp Farma S.L., Vedanta Biosciences, Astellas Pharma, Intrommune Therapeutics, Genentech, ASIT biotech, BlueWillow Biologics, Allergy Therapeutics, Alladapt Immunotherapeutics, Desentum, Camallergy, Prota Therapeutics, IgGenix, among others.
• Pipeline Therapies Assessed: Dupilumab, AR101, CNP-201, Etokimab, HAL-MPE1, ASP0892, INT301, etc.
• Therapeutic Dimensions Covered: Product type, clinical development stage, ROA, target receptor, mechanism of action, molecule type, and monotherapy vs. combination therapy.

Get Detailed Insights about the Reports Offerings @ https://www.delveinsight.com/sample-request/peanut-allergy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Introduction
2. Executive Summary
3. Peanut Allergy: Disease Overview
4. Pipeline Therapeutics Landscape
5. Therapeutic Assessment
6. Analytical Perspective by DelveInsight
7. Late-Stage Products (Phase III) - DBV712
8. Mid-Stage Products (Phase II) - PVX-108
9. Early-Stage Products (Phase I/II) - INP20
10. Preclinical & Discovery Stage Products
11. Inactive/Dormant Programs
12. Key Companies & Products
13. Unmet Needs in Peanut Allergy Management
14. Market Drivers and Barriers
15. Future Perspectives and Conclusion
16. Analyst Views
17. Appendix
18. About DelveInsight

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a global market research and consulting organization specializing in healthcare and life sciences. With a focus on therapeutics, medical devices, and diagnostics, the firm provides actionable intelligence and end-to-end strategic solutions to support clients in making data-driven business decisions.

This release was published on openPR.